NASDAQ Composite ended the session with Amicus Therapeutics jumping 4.47% to $10.28 on Monday while nASDAQ Composite fell 0.48% to $13,895.12.
Amicus Therapeutics today’s close was $10.28, 146.98% below its 52-week high of $25.39.
Amicus Therapeutics’s Sales
Amicus Therapeutics’s sales growth is 18.4% for the current quarter and 20.6% for the next. The company’s growth estimates for the ongoing quarter is 31.4% and a drop 10% for the next.
Amicus Therapeutics’s Revenue
Year-on-year quarterly revenue growth grew by 27.6%, now sitting on 260.89M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Amicus Therapeutics’s stock is considered to be overbought (>=80).
Amicus Therapeutics’s Stock Yearly Top and Bottom Value
Amicus Therapeutics’s stock is valued at $10.28 at 17:33 EST, way under its 52-week high of $25.39 and way above its 52-week low of $8.83.
Amicus Therapeutics’s Moving Average
Amicus Therapeutics’s worth is below its 50-day moving average of $10.76 and way under its 200-day moving average of $17.69.
More news about Amicus Therapeutics.